1-3 of 3
Michel Eichelbaum
Close
Sort by
Journal Articles

Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study Group.

Martin Stanulla, MD, Elke Schäffeler, PhD, Silke Pohlschmidt, Martin Zimmermann, PhD, Anja Möricke, MD, Gunnar Cario, MD, Andre Schrauder, MD, Karl Welte, MD, Jochen Harbott, PhD, Wolf-Dieter Ludwig, MD, Alfred Reiter, MD, Michel Eichelbaum, MD, Martin Schrappe, MD, Matthias Schwab, MD
Journal: Blood
Blood (2009) 114 (22): 2625.
https://doi.org/10.1182/blood.V114.22.2625.2625
Published: 2009
Journal Articles

Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols

Brief Report
Martin Stanulla, Elke Schaeffeler, Anja Möricke, Sally A. Coulthard, Gunnar Cario, André Schrauder, Peter Kaatsch, Michael Dördelmann, Karl Welte, Martin Zimmermann, Alfred Reiter, Michel Eichelbaum, Hansjörg Riehm, Martin Schrappe, Matthias Schwab
Journal: Blood
Blood (2009) 114 (7): 1314–1318.
https://doi.org/10.1182/blood-2008-12-193250
Published: 2009
Journal Articles

Thiopurine methyltransferase Genotype Is Not a Risk Factor for Secondary Malignant Neoplasias after Treatment for Childhood Acute Lymphoblastic Leukemia on Berlin-Frankfurt-Muenster Protocols.

Martin Stanulla, MD, Elke Schaeffeler, PhD, Anja Moericke, MD, Gunnar Cario, MD, Michel Eichelbaum, MD, Hansjoerg Riehm, MD, Karl Welte, MD, Martin Schrappe, MD, Matthias Schwab, MD
Journal: Blood
Blood (2006) 108 (11): 150.
https://doi.org/10.1182/blood.V108.11.150.150
Published: 2006